INTS intensitytherapeutics.com: Enterprise Value to EBITDA Ratio
Intensity Therapeutics assets are subject to binary risks due to a bet on a single breast cancer therapy drug. The company is implementing an injectable method that transforms a neoplasm into a personalized immune stimulant against metastases. This price chart confirms the value of the Dextran ecosystem, which creates a closed patent perimeter, while the EV/EBITDA ratio stands at 0.00.
Summary analytical data breakdowns for intensitytherapeutics.com (INTS)
- stock price and consensus target price:
- company stock capitalization data:
- business book valuation details:
- debt and solvency information:
Debt to Equity Intensity Therapeutics|INTS - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Intensity Therapeutics, Inc.|INTS - Company Aggregate Debts|Debt to Book Capitalization Ratio INTS|INTS - Company Long-Term Indebtedness|Company Short-Term Debt Intensity Therapeutics|Quick Liquidity Indicator intensitytherapeutics.com
- financial results and valuation multiples details:
INTS - Annual Net Income|Future Profit Intensity Therapeutics|INTS - Market Price to Net Income Ratio|Forward P/E Multiple Intensity Therapeutics, Inc.|INTS - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple INTS|INTS - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Intensity Therapeutics|INTS - Earnings per share for the trailing year|Quarterly EPS earnings growth intensitytherapeutics.com|INTS - Earnings growth in current year|Net earnings per share growth forecast for next year Intensity Therapeutics
Fundamental company analysis:INTS (Intensity Tx)
The strong pricing power of Intensity Therapeutics (INTS), driven by the uniqueness of the DIGNIT platform in cancer therapy, establishes a foundation for operating profit growth. By analyzing the company's EV/EBITDA ratio on this chart, an investor assesses the total enterprise value (market capitalization plus net debt) relative to its ability to generate cash flow before taxes and amortization, which determines the company's actual resilience under a high debt load.
Competitor analysis for Intensity Therapeutics
ImmunityBio Corp - Enterprise Value to EBITDA Ratio|Immunocore Corp (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (arcusbio.com)|ZYME: EV/EBITDA Multiple|TNGX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Iovance|Enterprise Value to EBITDA Ratio Immatics Biotechnologies (IMTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xencor, Inc. (XNCR)|Enterprise Value to EBITDA Ratio compasstherapeutics.com CMPX|Replimune - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Lyell LYEL|IPHA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PYXS (Pyxis Oncology, Inc.) - Enterprise Value to Operating Income Before Depreciation|cgen.com (CGEN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA iobiotech.com (IOBT)|Enterprise Value to EBITDA Ratio STRO|INKT - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio HOWL (Werewolf Therapeutics)|Enterprise Value to Operating Income Before Depreciation Ratio IMMX|EV/EBITDA Multiple ALXO (ALX Oncology)|Business Value to Operating Income Before Depreciation CUE|PDS Biotechnology Corp - EV/EBITDA Multiple|Company Value to EBITDA Sonnet BioTherapeutics|MAIA Biotechnology Inc (MAIA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Liminatus - Business Value to Operating Income Before Depreciation|LVTX (LAVA Therapeutics NV) - EV/EBITDA Multiple|EV/EBITDA Multiple nextcure.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Leap Therapeutics, Inc. (LPTX)|SNSE: Company Value to Operating Income Before Depreciation Ratio|Synthetic Biologics - Enterprise Value to EBITDA Ratio|Gritstone bio Inc. (GRTS) - Company Value to EBITDA|Kineta, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio neximmune.com NEXI|turnstonebio.com (TSBX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation VCNX|Enterprise Value to EBITDA Ratio HARP
